http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103735552-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2014-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103735552-B |
| titleOfInvention | Pharmaceutical composition of ticagrelor and cilostazol and its preparation method and application |
| abstract | The present invention relates to the pharmaceutical composition of ticagrelor and cilostazol, said composition has the effect suppressing or reverse arterial vascular medicated porridge sample Lipid Plaque, especially in the effect suppressing or reverse coronary artery or carotid medicated porridge sample Lipid Plaque, and the preparation method of described pharmaceutical composition, the invention still further relates to the application of aforementioned pharmaceutical compositions in medicine; Said composition effectively can solve and miss ticagrelor and the drug effect " vacuum phase " produced sporadicly, reduce contingent cardiocerebrovasculaevents events, in addition, significantly can also reduce the degree of gastrointestinal hemorrhage, be far smaller than combinationally using of ticagrelor and aspirin. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019170244-A1 |
| priorityDate | 2014-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.